1. Dubey S and Powell CA. Update in lung
cancer 2008. Am J Respir Crit Care Med
2009; 179: 860–868.
2. Matsuda T, Marugame T, Kamo KI, et al.
Cancer incidence and incidence rates in Japan
in 2005: based on data from 12 Populationbased Cancer Registries in the Monitoring of
Cancer Incidence in Japan (MCIJ) Project.
Jpn J Clin Oncol 2001; 41: 139–147.
3. Rami-Porta R, Ball D, Crowley J, et al. The
IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors
in the forthcoming (seventh) edition of the
TNM classification for lung cancer. J Thorac
Oncol 2007; 2: 593–602.
4. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.
5. Brenner DR, Scherer D, Muir K, et al.
A review of the application of inflammatory
biomarkers
in
epidemiologic
cancer
research. Cancer Epidemiol Biomarkers
Prev 2014; 23: 1729–1751.
6. Ballaz S and Mulshine JL. The potential
contributions of chronic inflammation to
lung carcinogenesis. Clin Lung Cancer
2003; 5: 46–62.
7. Allavena P, Garlanda C, Borrello MG, et al.
Pathways connecting inflammation and
cancer. Curr Opin Genet Dev 2008; 18: 3–10.
8. Engels EA. Inflammation in the development of lung cancer: epidemiological
14.
15.
16.
17.
18.
19.
20.
evidence. Expert Rev Anticancer Ther 2008;
8: 605–615.
Mantovani A, Allavena P, Sica A, et al.
Cancer-related inflammation. Nature 2008;
454: 436–444.
Azad N, Rojanasakul Y and Vallyathan V.
Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J Toxicol
Environ Health B Crit Rev 2008; 11: 1–15.
Tahara E. Growth factors and oncogenes
in human gastrointestinal carcinomas.
J Cancer Res Clin Oncol 1990; 116: 121–131.
Agnola CD and Biragyn A. Clinical utilization of chemokines to combat cancer: the
double-edged sword. Expert Rev Vaccines
2007; 6: 267–283.
Wong DT. Salivary Diagnostics: Amazing
as it might seem, doctors can detect and
monitor diseases using molecules found in
a sample of spit. Am Sci 2008; 96: 37–43.
Yamaguchi M and Shetty V. Salivary
Sensors for Quantification of Stress
Response
Biomarker.
Electrochemistry
2011; 79: 442–446.
Granger DA, Johnson SB, Szanton SL, et al.
Incorporating salivary biomarkers into nursing research: an overview and review of best
practices. Biol Res Nurs 2012; 14: 347–356.
Byrne ML, O’Brien-Simpson NM, Reynolds
EC, et al. Acute phase protein and cytokine
levels in serum and saliva: a comparison of
detectable levels and correlations in a
depressed and healthy adolescent sample.
Brain Behav Immun 2013; 34: 164–175.
Kamatani T, Shiogama S, Yoshihama Y,
et al. Interleukin-1 beta in unstimulated
whole saliva is a potential biomarker for
oral squamous cell carcinoma. Cytokine
2013; 64: 497–502.
Rathnayake N, Akerman S, Klinge B, et al.
Salivary biomarkers for detection of systemic diseases. PLoS One 2013; 8: e61356.
Tomas I, Arias-Bujanda N, AlonsoSampedro M, et al. Cytokine-based predictive models to estimate the probability of
chronic periodontitis: Development of diagnostic nomograms. Sci Rep 2017; 7: 11580.
Granger DA, Kivlighan KT, Fortunato C,
et al. Integration of salivary biomarkers into
developmental and behaviorally-oriented
research: problems and solutions for
Koizumi et al.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
collecting specimens. Physiol Behav 2007;
92: 583–590.
Shirtcliff EA, Granger DA, Schwartz E,
et al. Use of salivary biomarkers in
biobehavioral
research:
cotton-based
sample collection methods can interfere
with
salivary
immunoassay
results.
Psychoneuroendocrinol 2001; 26: 165–173.
Biancotto A, Feng X, Langweiler M, et al.
Effect of anticoagulants on multiplexed
measurement
of
cytokine/chemokines
in healthy subjects. Cytokine 2012;
60: 438–446.
Krishnan VV, Ravindran R, Wun T, et al.
Multiplexed measurements of immunomodulator levels in peripheral blood of healthy
subjects: Effects of analytical variables based
on anticoagulants, age, and gender.
Cytometry B Clin Cytom 2014; 86: 426–435.
Fernandez-Botran R, Miller JJ, Burns VE,
et al. Correlations among inflammatory
markers in plasma, saliva and oral mucosal
transudate in post-menopausal women with
past intimate partner violence. Brain Behav
Immun 2011; 25: 314–321.
Chiang JJ, Eisenberger NI, Seeman TE,
et al. Negative and competitive social interactions are related to heightened proinflammatory cytokine activity. Proc Natl Acad Sci
USA 2012; 109: 1878–1882.
Arellano-Garcia ME, Hu S, Wang J, et al.
Multiplexed immunobead-based assay for
detection of oral cancer protein biomarkers
in saliva. Oral Dis 2008; 14: 705–712.
Thorman R, Lundahl J, Yucel-Lindberg T,
et al. Inflammatory cytokines in saliva: early
signs of metabolic disorders in chronic
kidney disease. A controlled cross-sectional
study. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod 2010; 110: 597–604.
Kleinbaum DG and Klein M. Logistic
regression. 3rd ed. New York: Springer
ScienceþBusiness Media LCC, 2010,
pp. 1–32.
DeLong ER, DeLong DM and ClarkePearson DL. Comparing the areas under
two or more correlated receiver operating
characteristic curves: a nonparametric
approach. Biometrics 1988; 44: 837–845.
Kezic S, O’Regan GM, Lutter R, et al.
Filaggrin loss-of-function mutations are
3581
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
associated with enhanced expression of
IL-1 cytokines in the stratum corneum of
patients with atopic dermatitis and in a
murine model of filaggrin deficiency.
Allergy
Clin
Immunol
2012;
129: 1031–1039.
Attur M, Wang HY, Kraus VB, et al.
Radiographic severity of knee osteoarthritis
is conditional on interleukin 1 receptor
antagonist gene variations. Ann Rheum Dis
2010; 69: 856–861.
Agorastos A, Hauger RL, Barkauskas DA,
et al. Circadian rhythmicity, variability and
correlation of interleukin-6 levels in plasma
and cerebrospinal fluid of healthy men.
Psychoneuroendocrinol 2014; 44: 71–82.
Geiger SS, Fagundes CT, Siegel RM.
Chrono-immunology: progress and challenges in understanding links between
the circadian and immune systems.
Immunology 2015; 146: 349–358.
Khan A. Detection and quantitation of forty
eight cytokines, chemokines, growth factors
and nine acute phase proteins in healthy
human
plasma,
saliva
and
urine.
J Proteomics 2012, 75: 4802–4819.
Daly S, Rinewalt D, Fhied C, et al.
Development and validation of a plasma
biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol: IASLC 2013, 8: 31–36.
DeCotiis C, Hu Y, Greenberg AK, et al.
Inflammatory cytokines and non-small cell
lung cancer in a CT-scan screening cohort:
Background review of the literature. Cancer
Biomark 2016; 16: 219–233.
Kullmann T, Barta I, Csisze´r E, et al.
Differential cytokine pattern in the exhaled
breath of patients with lung cancer. Pathol
Oncol Res 2008; 14: 481–483.
Shih CM, Lee YL, Chiou HL, et al. The
involvement of genetic polymorphism of
IL-10 promoter in non-small cell lung
cancer. Lung Cancer 2005; 50: 291–297.
Arenberg DA, White ES, Burdick MD, et al.
Improved survival in tumor-bearing SCID
mice treated with interferon-c-inducible protein 10 (IP-10/CXCL10). Cancer Immunol
Immunother 2001; 50: 533–538.
De Vita F, Orditura M, Galizia G, et al.
Serum interleukin-10 levels as a prognostic
3582
factor in advanced non-small cell lung
cancer patients. Chest 2000; 117: 365–373.
41. Arenberg DA, Kunkel SL, Polverini PJ,
et al. Interferon-y-inducible Protein 10
(IP-10) Is an Angiostatic Factor That
Inhibits Human Non-small Cell Lung
Journal of International Medical Research 46(9)
Cancer (NSCLC) Tumorigenesis and
Spontaneous Metastases. J Exp Med 1996;
184: 981–992.
42. Belperio JA, Keane MP, Arenberg DA, et al.
CXC
chemokines
in
angiogenesis.
J Leukocyte Biol 2000; 68: 1–8.
...
論文の公開元へ
